Targeting and exploiting macropinocytosis in cancer therapy

Area of Science:

• Oncology
• Cell Biology
• Nanotechnology

Background:

• Macropinocytosis is crucial for cancer cell survival and is often hyperactivated in cancers with KRAS mutations or PTEN deficiencies.
• Current strategies focus on inhibiting macropinocytosis to starve cancer cells, but nanotechnology offers a novel therapeutic avenue.

Purpose of the Study:

• To examine the molecular mechanisms regulating macropinocytosis in cancer.
• To explore strategies for inhibiting and therapeutically exploiting macropinocytosis in cancer treatment.
• To highlight innovations in engineered therapeutics for selective drug delivery via macropinocytosis.

Main Methods:

• Review of molecular mechanisms of macropinocytosis regulation in cancer.
• Analysis of intrinsic factors (oncogenic mutations) and extrinsic factors (tumor microenvironment).
• Examination of nanotechnology-based drug delivery systems targeting macropinocytosis.

Main Results:

• Engineered therapeutics (nanoparticles, conjugates) leverage elevated macropinocytosis for enhanced drug uptake in tumor cells.
• This targeted delivery improves treatment efficacy and minimizes off-target effects.
• Modulating macropinocytosis presents opportunities for personalized cancer therapies.

Conclusions:

• Macropinocytosis is a key target for cancer therapy, with nanotechnology offering innovative solutions for selective drug delivery.
• Addressing challenges like tumor heterogeneity and drug resistance is crucial for clinical translation.
• Targeting macropinocytosis holds promise for more effective and personalized cancer treatments.